Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.


Journal

Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469

Informations de publication

Date de publication:
06 03 2021
Historique:
received: 17 11 2020
accepted: 19 02 2021
revised: 18 02 2021
entrez: 7 3 2021
pubmed: 8 3 2021
medline: 8 1 2022
Statut: epublish

Résumé

Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN) characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone marrow, mainly due to a Janus kinase 2 gene mutation (JAK2

Identifiants

pubmed: 33677466
doi: 10.1038/s41408-021-00445-z
pii: 10.1038/s41408-021-00445-z
pmc: PMC7936975
doi:

Substances chimiques

Carbamates 0
Histone Deacetylase Inhibitors 0
givinostat 5P60F84FBH

Types de publication

Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53

Références

Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Ann Hematol. 2019 Jun;98(6):1421-1426
pubmed: 30919072
Trends Mol Med. 2005 Dec;11(12):546-54
pubmed: 16271512
Mol Med. 2011 May-Jun;17(5-6):353-62
pubmed: 21365126
Leukemia. 2020 Aug;34(8):2234-2237
pubmed: 32047238
Ann Hematol. 2010 Feb;89(2):185-90
pubmed: 19633847
Blood. 2014 Jun 12;123(24):3803-10
pubmed: 24553173
Br J Haematol. 2010 Aug;150(4):446-55
pubmed: 20560970
Neuromuscul Disord. 2016 Oct;26(10):643-649
pubmed: 27566866
Br J Haematol. 2019 Jan;184(2):176-191
pubmed: 30478826
Exp Hematol. 2012 Aug;40(8):634-45.e10
pubmed: 22579713
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Blood Cancer J. 2015 Nov 13;5:e366
pubmed: 26565403
Blood Cancer J. 2018 Feb 9;8(2):15
pubmed: 29426921
Exp Hematol. 2013 Mar;41(3):253-60.e2
pubmed: 23111067
Clin Adv Hematol Oncol. 2017 Nov;15(11):848-850
pubmed: 29200417
Curr Treat Options Oncol. 2020 Apr 30;21(6):46
pubmed: 32350623
Blood. 2019 Oct 31;134(18):1498-1509
pubmed: 31515250
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Leukemia. 2008 Nov;22(11):1990-8
pubmed: 18843285
Blood. 2005 Oct 15;106(8):2849-53
pubmed: 15994287
Blood. 2006 Jun 1;107(11):4214-22
pubmed: 16484586
Mol Med. 2011 May-Jun;17(5-6):363-8
pubmed: 21274502
Blood. 2009 May 14;113(20):4829-33
pubmed: 19278953
Leukemia. 2008 Apr;22(4):740-7
pubmed: 18079739
Br J Haematol. 2013 Jun;161(5):688-94
pubmed: 23573950
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Cancer. 2006 Feb 1;106(3):631-5
pubmed: 16369984
Int J Hematol. 2020 Feb;111(2):182-191
pubmed: 31741139
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187

Auteurs

Alessandro Rambaldi (A)

Department of Oncology and Hematology University of Milan, and Azienda SocioSanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. alessandro.rambaldi@unimi.it.

Alessandra Iurlo (A)

Hematology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Alessandro M Vannucchi (AM)

Center Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Florence, Italy.

Bruno Martino (B)

Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Haematology Unit, Reggio Calabria, Italy.

Attilio Guarini (A)

Hematology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Marco Ruggeri (M)

U.O. Haematology, San Bortolo Hospital, Vicenza, Italy.

Nikolas von Bubnoff (N)

Department of Haematology, Oncology and Stem Cell Transplantation, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Department of Haematology and Oncology, Medical Center, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Marianna De Muro (M)

Hematology and Stem Cells Transplantation Unit, Campus Bio-Medico, University Hospital, Rome, Italy.

Mary Frances McMullin (MF)

Centre for Medical Education, Queen's University Belfast, Belfast, United Kingdom.

Stefania Luciani (S)

Dipartimento Oncologia-Ematologia, U.O. Complessa Ematologia Clinica, Presidio Ospedaliero "Spirito Santo"- A.S.L. Azienda Sanitaria Locale, Pescara, Italy.

Vincenzo Martinelli (V)

Dipartimento di Medicina Clinica e Chirurgia, Ematologia, Università degli Studi di Napoli Federico II, Naples, Italy.

Axel Nogai (A)

Division of Hematology and Oncology at Campus Benjamin Franklin (CBF), Charité, Berlin, Germany.

Vittorio Rosti (V)

Fondazione I.R.C.C.S. Policlinico San Matteo di Pavia, Centro per lo Studio e la Cura della Mielofibrosi, Laboratorio Biochimica, Biotecnologie e Diagnostica Avanzata, Pavia, Italy.

Alessandra Ricco (A)

Azienda Ospedaliero-Universitaria Policlinico Consorziale di Bari, U. O. Ematologia con Trapianto - Ambulatorio, Bari, Italy.

Paolo Bettica (P)

Clinical R&D Department, Italfarmaco S.p.A, Cinisello Balsamo, Italy.

Sara Manzoni (S)

Clinical R&D Department, Italfarmaco S.p.A, Cinisello Balsamo, Italy.

Silvia Di Tollo (S)

Clinical R&D Department, Italfarmaco S.p.A, Cinisello Balsamo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH